
US-based Biogen has dropped the price of its Alzheimer's treatment Aduhelm by fifty percent, Bloomberg News reports.
This has happened to light a fire under the sales, which have stagnated since the product's launch, partially because of its high price tag.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app